Albert Bourla, CEO of Pfizer

  • EU summit to speed up vaccines.

    Hearings and pressure on Big Pharma

Share

February 25, 2021

The US pharmaceutical company Pfizer, based in New York, has identified and entered into negotiations with eleven companies with plants in Europe to expand the production of its anti-Covid vaccine, most of them located in Germany, others in Switzerland.

Plants identified in Europe include the plants of Delpharm, Sanofi, Merck KGAa, Novartis, Polymun, DermaPharm, BioNTech Marburg, BioNTech Mainz and Rentschler.

Each plant will participate in the production of the vaccine based on its technologies and the type of plant, it was explained.